Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Rises Again, While Cepheid Shares Drop

Shares of Sequenom have risen sharply for the fourth week in a row, climbing 11.5 percent for the five-day trading period ended Tuesday to lead all stocks in the BCW Index. Sequenom’s shares have doubled over the past month as the firm in-licensed rights to a next-generation sequencing technology and launched a new assay design and validation service.
Cepheid, whose shares have risen throughout the year, led decliners in the Index this week with a drop of 10.1 percent as investors took profits. Its shares had a strong Tuesday, though, gaining 4.2 percent after the firm was mentioned during a CNBC report on hospital Staph infections.
Overall, the Index dropped .7 percent for the tracking period. In comparison, the Dow Jones Industrial Average fell 1.8 percent, the Nasdaq dropped 1.4 percent, and the Nasdaq Biotech Index bucked the trend by closing up .2 percent for the week.

File Attachments
The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.